Eli Lilly Begins Phase 3 Trial of Monoclonal Antibody for COVID-19 Prevention
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for prevention of COVID-19 in residents and staff at long-term care facilities.
The study will test if a single dose reduces the rate of SARS-CoV-2 infection through four weeks and COVID-19 complications through eight weeks. It will enroll up to 2,400 residents and staff at facilities that have had a recently diagnosed case of COVID-19 and who are at a high risk of exposure.
The trial will be conducted in collaboration with the NIH’s National Institute of Allergy and Infectious Diseases.